Moderna, Inc. (MRNA) EV/EBITDA Ratio: N/A
The EV/EBITDA ratio for Moderna, Inc. (MRNA) is N/A as of Wednesday, June 10, 2026.
MRNA EV/EBITDA Ratio Chart
MRNA Average EV/EBITDA Ratio Chart
MRNA EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
12.39x
EV/EBITDA RATIO AVG 3Y
25.27x
EV/EBITDA RATIO AVG 5Y
25.27x
EV/EBITDA RATIO AVG 10Y
25.27x
EV/EBITDA RATIO AVG 15Y
25.27x
EV/EBITDA RATIO AVG 20Y
25.27x
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MRNA Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | — | N/A | 12.39x | 25.27x | 25.27x |
| Hologic, Inc. (HOLX) | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| BioNTech SE (BNTX) | $21.81B | N/A | 51.40x | 19.63x | 20.05x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 20.28x | 23.56x | 23.88x | 26.50x |
| Waters Corporation (WAT) | $23.83B | 38.03x | 21.59x | 21.24x | 21.45x |
| Align Technology, Inc. (ALGN) | $12.56B | 14.39x | 13.92x | 20.40x | 25.91x |
| Veeva Systems Inc. (VEEV) | $26.73B | 25.37x | 43.29x | 56.90x | 62.37x |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 15.01x | 19.03x | 15.54x | 17.41x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 252.70x | 57.93x | 92.86x | 47.74x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Moderna, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The EV/EBITDA ratio for MRNA stock is N/A.
- What is the TTM average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The TTM average EV/EBITDA ratio for MRNA stock is 12.39x.
- What is the 3Y average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The 3Y average EV/EBITDA ratio for MRNA stock is 25.27x.
- What is the 5Y average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The 5Y average EV/EBITDA ratio for MRNA stock is 25.27x.
- What is the 10Y average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The 10Y average EV/EBITDA ratio for MRNA stock is 25.27x.
- What is the 15Y average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The 15Y average EV/EBITDA ratio for MRNA stock is 25.27x.
- What is the 20Y average EV/EBITDA ratio for Moderna, Inc. (MRNA)?
- The 20Y average EV/EBITDA ratio for MRNA stock is 25.27x.
Moderna, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2023-11-02 | 20.10x |
| 2023-11-01 | 21.66x |
| 2023-10-31 | 21.58x |
| 2023-10-30 | 20.99x |
| 2023-10-27 | 20.32x |
| 2023-10-26 | 21.59x |
| 2023-10-25 | 21.83x |
| 2023-10-24 | 22.77x |
| 2023-10-23 | 22.42x |
| 2023-10-20 | 22.97x |
| 2023-10-19 | 23.58x |
| 2023-10-18 | 24.72x |
| 2023-10-17 | 24.82x |
| 2023-10-16 | 26.58x |
| 2023-10-13 | 28.56x |
| 2023-10-12 | 29.34x |
| 2023-10-11 | 29.96x |
| 2023-10-10 | 30.48x |
| 2023-10-09 | 29.67x |
| 2023-10-06 | 30.31x |
| 2023-10-05 | 30.02x |
| 2023-10-04 | 30.43x |
| 2023-10-03 | 30.06x |
| 2023-10-02 | 30.13x |
| 2023-09-29 | 30.12x |
| 2023-09-28 | 29.18x |
| 2023-09-27 | 28.92x |
| 2023-09-26 | 28.51x |
| 2023-09-25 | 28.52x |
| 2023-09-22 | 29.09x |
| 2023-09-21 | 29.17x |
| 2023-09-20 | 30.20x |
| 2023-09-19 | 31.20x |
| 2023-09-18 | 30.39x |
| 2023-09-15 | 33.66x |
| 2023-09-14 | 33.10x |
| 2023-09-13 | 31.78x |
| 2023-09-12 | 30.73x |
| 2023-09-11 | 30.91x |
| 2023-09-08 | 31.48x |
| 2023-09-07 | 31.70x |
| 2023-09-06 | 31.67x |
| 2023-09-05 | 32.02x |
| 2023-09-01 | 33.02x |
| 2023-08-31 | 33.18x |
| 2023-08-30 | 34.29x |
| 2023-08-29 | 34.09x |
| 2023-08-28 | 33.42x |
| 2023-08-25 | 32.82x |
| 2023-08-24 | 33.05x |
| 2023-08-23 | 33.93x |
| 2023-08-22 | 34.17x |
| 2023-08-21 | 32.56x |
| 2023-08-18 | 29.60x |
| 2023-08-17 | 31.05x |
| 2023-08-16 | 28.76x |
| 2023-08-15 | 27.97x |
| 2023-08-14 | 29.10x |
| 2023-08-11 | 29.56x |
| 2023-08-10 | 29.18x |
| 2023-08-09 | 29.66x |
| 2023-08-08 | 29.01x |
| 2023-08-07 | 29.47x |
| 2023-08-04 | 31.65x |
| 2023-08-03 | 32.21x |
| 2023-08-02 | 7.81x |
| 2023-08-01 | 8.08x |
| 2023-07-31 | 8.36x |
| 2023-07-28 | 8.44x |
| 2023-07-27 | 8.43x |
| 2023-07-26 | 8.58x |
| 2023-07-25 | 8.68x |
| 2023-07-24 | 8.76x |
| 2023-07-21 | 9.02x |
| 2023-07-20 | 8.89x |
| 2023-07-19 | 8.92x |
| 2023-07-18 | 8.73x |
| 2023-07-17 | 8.73x |
| 2023-07-14 | 8.64x |
| 2023-07-13 | 9.03x |
| 2023-07-12 | 8.98x |
| 2023-07-11 | 8.70x |
| 2023-07-10 | 8.77x |
| 2023-07-07 | 8.45x |
| 2023-07-06 | 8.41x |
| 2023-07-05 | 8.80x |
| 2023-07-03 | 8.67x |
| 2023-06-30 | 8.65x |
| 2023-06-29 | 8.69x |
| 2023-06-28 | 8.76x |
| 2023-06-27 | 8.59x |
| 2023-06-26 | 8.57x |
| 2023-06-23 | 8.42x |
| 2023-06-22 | 8.57x |
| 2023-06-21 | 8.62x |
| 2023-06-20 | 8.85x |
| 2023-06-16 | 9.19x |
| 2023-06-15 | 9.28x |
| 2023-06-14 | 8.99x |
| 2023-06-13 | 9.13x |
| 2023-06-12 | 8.80x |
| 2023-06-09 | 8.78x |
| 2023-06-08 | 8.91x |
| 2023-06-07 | 8.96x |
| 2023-06-06 | 9.05x |
| 2023-06-05 | 9.20x |
| 2023-06-02 | 9.32x |
| 2023-06-01 | 9.17x |
| 2023-05-31 | 9.11x |
| 2023-05-30 | 8.97x |
| 2023-05-26 | 9.00x |
| 2023-05-25 | 9.02x |
| 2023-05-24 | 9.40x |
| 2023-05-23 | 9.86x |
| 2023-05-22 | 9.04x |
| 2023-05-19 | 9.00x |
| 2023-05-18 | 8.93x |
| 2023-05-17 | 8.95x |
| 2023-05-16 | 8.92x |
| 2023-05-15 | 9.30x |
| 2023-05-12 | 9.23x |
| 2023-05-11 | 9.16x |
| 2023-05-10 | 9.35x |
| 2023-05-09 | 9.57x |
| 2023-05-08 | 9.41x |
| 2023-05-05 | 9.81x |
| 2023-05-04 | 9.61x |
| 2023-05-03 | 5.10x |
| 2023-05-02 | 5.15x |
| 2023-05-01 | 5.23x |
| 2023-04-28 | 5.21x |
| 2023-04-27 | 5.10x |
| 2023-04-26 | 5.12x |
| 2023-04-25 | 5.29x |
| 2023-04-24 | 5.42x |
| 2023-04-21 | 5.53x |
| 2023-04-20 | 5.55x |
| 2023-04-19 | 5.62x |
| 2023-04-18 | 5.61x |
| 2023-04-17 | 5.66x |
| 2023-04-14 | 6.20x |
| 2023-04-13 | 6.34x |
| 2023-04-12 | 6.13x |
| 2023-04-11 | 6.12x |
| 2023-04-10 | 6.32x |
| 2023-04-06 | 6.24x |
| 2023-04-05 | 6.10x |
| 2023-04-04 | 6.17x |
| 2023-04-03 | 6.29x |
| 2023-03-31 | 6.05x |
| 2023-03-30 | 5.80x |
| 2023-03-29 | 5.86x |
| 2023-03-28 | 5.78x |
| 2023-03-27 | 5.84x |
| 2023-03-24 | 5.94x |
| 2023-03-23 | 5.88x |
| 2023-03-22 | 5.83x |
| 2023-03-21 | 5.99x |
| 2023-03-20 | 6.09x |
| 2023-03-17 | 5.91x |
| 2023-03-16 | 5.98x |
| 2023-03-15 | 5.89x |
| 2023-03-14 | 5.96x |
| 2023-03-13 | 5.82x |
| 2023-03-10 | 5.43x |
| 2023-03-09 | 5.39x |
| 2023-03-08 | 5.59x |
| 2023-03-07 | 5.54x |
| 2023-03-06 | 5.66x |
| 2023-03-03 | 5.63x |
| 2023-03-02 | 5.41x |
| 2023-03-01 | 5.32x |
| 2023-02-28 | 5.45x |
| 2023-02-27 | 5.43x |
| 2023-02-24 | 5.47x |
| 2023-02-23 | 4.31x |
| 2023-02-22 | 4.63x |
| 2023-02-21 | 4.69x |
| 2023-02-17 | 4.89x |
| 2023-02-16 | 5.06x |
| 2023-02-15 | 5.21x |
| 2023-02-14 | 5.16x |
| 2023-02-13 | 5.03x |
| 2023-02-10 | 4.97x |
| 2023-02-09 | 4.82x |
| 2023-02-08 | 4.82x |
| 2023-02-07 | 5.02x |
| 2023-02-06 | 5.00x |
| 2023-02-03 | 5.09x |
| 2023-02-02 | 5.18x |
| 2023-02-01 | 5.12x |
| 2023-01-31 | 5.17x |
| 2023-01-30 | 5.32x |
| 2023-01-27 | 5.57x |
| 2023-01-26 | 5.69x |
| 2023-01-25 | 5.68x |
| 2023-01-24 | 5.79x |
| 2023-01-23 | 5.80x |
| 2023-01-20 | 5.71x |
| 2023-01-19 | 5.60x |
| 2023-01-18 | 5.80x |
| 2023-01-17 | 5.61x |
| 2023-01-13 | 5.65x |
| 2023-01-12 | 5.53x |
| 2023-01-11 | 5.49x |
| 2023-01-10 | 5.58x |
| 2023-01-09 | 5.41x |
| 2023-01-06 | 5.30x |
| 2023-01-05 | 5.09x |
| 2023-01-04 | 5.21x |
| 2023-01-03 | 5.26x |
| 2022-12-30 | 5.28x |
| 2022-12-29 | 5.25x |
| 2022-12-28 | 5.18x |
| 2022-12-27 | 5.29x |
| 2022-12-23 | 5.86x |
| 2022-12-22 | 6.14x |
| 2022-12-21 | 6.19x |
| 2022-12-20 | 5.93x |
| 2022-12-19 | 5.59x |
| 2022-12-16 | 5.69x |
| 2022-12-15 | 6.11x |
| 2022-12-14 | 6.16x |
| 2022-12-13 | 5.82x |
| 2022-12-12 | 4.84x |
| 2022-12-09 | 5.21x |
| 2022-12-08 | 5.43x |
| 2022-12-07 | 5.26x |
| 2022-12-06 | 5.09x |
| 2022-12-05 | 5.17x |
| 2022-12-02 | 5.36x |
| 2022-12-01 | 5.33x |
| 2022-11-30 | 5.17x |
| 2022-11-29 | 5.08x |
| 2022-11-28 | 5.15x |
| 2022-11-25 | 5.18x |
| 2022-11-23 | 5.19x |
| 2022-11-22 | 5.28x |
| 2022-11-21 | 5.19x |
| 2022-11-18 | 5.34x |
| 2022-11-17 | 5.41x |
| 2022-11-16 | 5.45x |
| 2022-11-15 | 5.45x |
| 2022-11-14 | 5.26x |
| 2022-11-11 | 5.02x |
| 2022-11-10 | 4.94x |
| 2022-11-09 | 4.78x |
| 2022-11-08 | 4.83x |
| 2022-11-07 | 4.81x |
| 2022-11-04 | 4.64x |
| 2022-11-03 | 4.31x |
| 2022-11-02 | 3.77x |
| 2022-11-01 | 3.93x |
| 2022-10-31 | 3.82x |
| 2022-10-28 | 3.84x |
| 2022-10-27 | 3.66x |
| 2022-10-26 | 3.60x |
| 2022-10-25 | 3.46x |
| 2022-10-24 | 3.36x |
| 2022-10-21 | 3.24x |
Showing the most recent 260 of 629 data points. The chart above shows the full history.
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel